All In Biotech

NDA 020941 · Haleon US Holdings

Abreva

Docosanol · Topical

Novel

Last checked: Nov 20, 2026Latest source record: Apr 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Jul 25, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

5

1 Phase 3, 0 recruiting

FAERS reports

14,600

280 serious, 9 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 20, 2024.

Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 25, 2000 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
1 products under this application
  • ABREVA · DOCOSANOL 10% · CREAM, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Docosanol" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective7,071
  • oral herpes2,458
  • condition aggravated1,967
  • drug administration error1,779
  • incorrect drug administration duration803
  • herpes simplex706
  • incorrect product administration duration642
  • lip swelling560
  • wrong technique in product usage process552
  • product quality issue539
  • inappropriate schedule of drug administration493
  • application site pain448

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045
20051,157
20061,355
20071,648
20085
200914
20109
201117
201213
20132,116
2014216
20151,337
2016974
20171,006
20181,074
2019855
2020479
2021453
2022333
2023852
2024344
2025219
2026119

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Haleon US Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.